According to a study using local epidemiological data in China, vaccinating infants with pneumococcal conjugate vaccine (PCV-13), using a 3+1 schedule, would prevent more than 10 times as many deaths from invasive pneumococcal disease and pneumonia in unvaccinated individuals (147,500 per year) than it would prevent directly in those vaccinated (12,800 per year). This would be due mainly to a reduction in hospitalizations for pneumonia.
Full Citation:
Shen K, Wasserman M, Liu D et al.. 2018. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS One. 13(7).
Title of Article: Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
Author(s): Shen K, Wasserman M, Liu D et al.
Publication Year: 2018
Publication Name: PLoS One
Publication Volume: 13(7)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059448/pdf/pone.0201245.pdf
DOI (Digital Object Identifier): 10.1371/journal.pone.0201245
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: China
WHO Regions: Western Pacific